- Clinical Trials
- April 2025
- 60 Pages
Global
From €1318EUR$1,500USD£1,140GBP
- Report
- April 2025
- 175 Pages
Global
From €3947EUR$4,490USD£3,414GBP
- Clinical Trials
- April 2025
- 180 Pages
Global
From €2197EUR$2,500USD£1,901GBP
- Report
- April 2025
- 200 Pages
Global
From €6988EUR$7,950USD£6,044GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1099EUR$1,250USD£950GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1099EUR$1,250USD£950GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1099EUR$1,250USD£950GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2451EUR$2,789USD£2,120GBP
- Report
- August 2023
- 150 Pages
United States
From €3296EUR$3,750USD£2,851GBP
- Report
- May 2023
- 196 Pages
Global
From €2197EUR$2,500USD£1,901GBP
P-Selectin is a type of hematological drug used to treat a variety of conditions related to the blood, such as thrombosis, inflammation, and cancer. It is a type of cell adhesion molecule that binds to other cells, allowing them to stick together and form clots. P-Selectin is also involved in the process of leukocyte rolling, which is important for the immune system to respond to infection.
P-Selectin is used in a variety of treatments, including anticoagulants, anti-inflammatory drugs, and cancer therapies. It is also used in research to study the role of cell adhesion molecules in the development of diseases.
The P-Selectin market is highly competitive, with many companies offering products for different applications. Some of the major players in the market include Merck, Pfizer, Novartis, Sanofi, and Bristol-Myers Squibb. Other companies include AstraZeneca, GlaxoSmithKline, and Roche. Show Less Read more